Long non-coding RNA MALAT1 modulate cell migration, proliferation and apoptosis by sponging microRNA-146a to regulate CXCR4 expression in acute myeloid leukemia

Sheng, Xianfu; Hong, Li-Li; Li, Hui; Huang, Feiyan; Wen, Qiang; Zhuang, Haifeng

doi:10.1080/16078454.2020.1867781

Cited by 23 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, the expression of Bax, Bak, HRK, TNFRSF10A and TNFRSF10B was increased in the metformin‐treated cells, indicating that metformin could possibly activate both extrinsic apoptosis and intrinsic apoptosis. Several reports have confirmed that MALAT1 knock‐down could trigger activation of apoptosis in cancer cells 20,21 . In the present study, it also found that the expression of pro‐apoptotic Bcl‐2 members was further enhanced in the metformin‐treated cells with MALAT1 knock‐down, indicating that metformin treatment in combination with MALAT1 knock‐down is more conducive to apoptosis induction than metformin treatment alone.…”

Section: Discussionsupporting

confidence: 84%

“…Several reports have confirmed that MALAT1 knock-down could trigger activation of apoptosis in cancer cells. 20,21 In the present study, it also found that the expression of pro-apoptotic Bcl-2 members was further enhanced in the metformin-treated cells with MALAT1 knock-down, indicating that metformin treatment in combination with MALAT1 knock-down is more conducive to apoptosis induction than metformin treatment alone.…”

Section: Discussionsupporting

confidence: 63%

See 1 more Smart Citation

lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell

Huang

Zhou

Zhang

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

In recent years, the repurposing of conventional and chemotherapeutic drugs is recognized as an alternative strategy for health care. The main purpose of this study is to strengthen the application of non‐oncological drug metformin on breast cancer treatment in the perspective of epigenetics. In the present study, metformin was found to inhibit cell proliferation, promote apoptosis and induce cell cycle arrest in breast cancer cells at a dose‐dependent manner. In addition, metformin treatment elevated acH3K9 abundance and decreased acH3K18 level. The expression of lncRNA MALAT1, HOTAIR, DICER1‐AS1, LINC01121 and TUG1 was up‐regulated by metformin treatment. In metformin‐treated cells, MALAT1 knock‐down increased the Bax/Bcl2 ratio and enhanced p21 but decreased cyclin B1 expression. The expression of Beclin1, VDAC1, LC3‐II, CHOP and Bip was promoted in the cells received combinatorial treatment of metformin and MALAT1 knock‐down. The reduced phosphorylation of c‐Myc was further decreased in the metformin‐treated cells in combination with MALAT1 knock‐down than metformin treatment alone. Taken together, these results provide a promising repurposed strategy for metformin on cancer treatment by modulating epigenetic modifiers.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 63%

lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell

Huang

Zhou

Zhang

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…On the other hand, MALAT1 can also regulate gene expression post-transcriptionally by acting as a ceRNA sequestering miRNAs. For example, in acute myeloid leukemia, MALAT1 regulates cells migration, proliferation and apoptosis, by releasing CXCR4 from the regulatory inhibition of hsa-miR-146 [ 38 ]. In multiple myeloma, MALAT1 regulates proliferation and adhesion of multiple myeloma cells via hsa-miR-181-5p/Hippo-YAP axis.…”

Section: Discussionmentioning

confidence: 99%

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

Fernandes

Marques

Teixeira

et al. 2021

IJMS

View full text Add to dashboard Cite

Research has been focusing on identifying novel biomarkers to better stratify non-Hodgkin lymphoma patients based on prognosis. Studies have demonstrated that lncRNAs act as miRNA sponges, creating ceRNA networks to regulate mRNA expression, and its deregulation is associated with lymphoma development. This study aimed to identify novel circulating prognostic biomarkers based on miRNA/lncRNA-associated ceRNA network for NHL. Herein, bioinformatic analysis was performed to construct ceRNA networks for hsa-miR-150-5p and hsa-miR335-5p. Then, the prognostic value of the miRNA–lncRNA pairs’ plasma levels was assessed in a cohort of 113 NHL patients. Bioinformatic analysis identified MALAT1 and NEAT1 as hsa-miR-150-5p and has-miR-335-5p sponges, respectively. Plasma hsa-miR-150-5p/MALAT1 and hsa-miR335-5p/NEAT1 levels were significantly associated with more aggressive and advanced disease. The overall survival and progression-free survival analysis indicated that hsa-miR-150-5p/MALAT1 and hsa-miR335-5p/NEAT1 pairs’ plasma levels were remarkably associated with NHL patients’ prognosis, being independent prognostic factors in a multivariate Cox analysis. Low levels of hsa-miR-150-5p and hsa-miR-335-5p combined with high levels of the respective lncRNA pair were associated with poor prognosis of NHL patients. Overall, the analysis of ceRNA network expression levels may be a useful prognostic biomarker for NHL patients and could identify patients who could benefit from more intensive treatments.

show abstract

“…LncRNA MALAT1 and CXCR4 were upregulated, while miR-146a was downregulated in AML patients compared with healthy controls. MALAT1 promotes migration and proliferation of AML cells by sponging miR-146a and stimulating CXCR4 expression [70].…”

Section: Mirnas and Lncrnas Interactionmentioning

confidence: 99%

Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers

Anelli

Zagaria

Specchia

et al. 2021

IJMS

View full text Add to dashboard Cite

Micro RNAs (miRNAs) are a class of small non-coding RNAs that have a crucial role in cellular processes such as differentiation, proliferation, migration, and apoptosis. miRNAs may act as oncogenes or tumor suppressors; therefore, they prevent or promote tumorigenesis, and abnormal expression has been reported in many malignancies. The role of miRNA in leukemia pathogenesis is still emerging, but several studies have suggested using miRNA expression profiles as biomarkers for diagnosis, prognosis, and response to therapy in leukemia. In this review, the role of miRNAs most frequently involved in leukemia pathogenesis is discussed, focusing on the class of circulating miRNAs, consisting of cell-free RNA molecules detected in several body fluids. Circulating miRNAs could represent new potential non-invasive diagnostic and prognostic biomarkers of leukemia that are easy to isolate and characterize. The dysregulation of some miRNAs involved in both myeloid and lymphoid leukemia, such as miR-155, miR-29, let-7, and miR-15a/miR-16-1 clusters is discussed, showing their possible employment as therapeutic targets.

show abstract

Long non-coding RNA MALAT1 modulate cell migration, proliferation and apoptosis by sponging microRNA-146a to regulate CXCR4 expression in acute myeloid leukemia

Cited by 23 publications

References 35 publications

lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell

lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers

Contact Info

Product

Resources

About